Navigation Links
NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD

NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD -- NESS ZIONA, Israel, November 9, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD


NESS ZIONA, Israel, November 9, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

Nicotinic brain circuitry has previously been shown to be involved in a variety of neurological diseases and disorders and, consequently, nicotinic receptors are the target of several agonist drugs under development. Nicotine, however, has had limited potential as a drug because its repeated use downregulates the actions of the nicotinic receptors. Based on pre-clinical studies, ND0801 is believed to work by preventing the desensitization of nicotinic receptors (contributing to nicotine addiction) that otherwise occurs as a result of repeat nicotine applications. The company hopes that, should it overcome the desensitization of nicotine effects, ND0801 may be beneficial in the treatment of cognitive and other central nervous system dysfunctions.

This Phase 2a study, conducted at two centers in Israel, is planned to enroll 45 ADD/ADHD patients. The trial will examine the safety, tolerability and optimal therapeutic dose of ND0801, and will evaluate the cognitive improvement in these subjects following treatment with ND0801, using standard cognition scale tests.

"The start of this clinical study with ND0801 is a major milestone for NeuroDerm. It marks the entry into clinical development of the company's second, innovative product, for the treatment of cognitive impairment," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "Nicotine is believed to have great potential for the treatment of many diseases. We hope that ND0801 might become the first patch to overcome the desensitization of nicotinic receptors, thereby offering an exciting new treatment option in CNS diseases."

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapeutic dermal patches for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations and/or combinations of well established drugs to achieve a new clinical effect or improved clinical benefit. The company's clinical stage products include ND0611, a skin patch for the treatment of Parkinson's disease and ND0801, for the treatment of cognitive dysfunctions in ADD/ADHD and other CNS diseases. Other products for the treatment of various CNS diseases are in different stages of development. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact: Oded S. Lieberman, PhD MBA, Chairman & CEO Tel.: +972-8-946 2729; Cell: +1-617-517 6077

SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
2. American Regent Initiates Voluntary Recall of Magnesium Sulfate Injection, USP 50% (25 grams/50 mL), 50mL Single Dose Vial Lot # 0491
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
5. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
6. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
7. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
8. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
9. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
10. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
11. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Post Your Comments:
(Date:10/9/2015)... , October 9, 2015 ... major players. --> India ... --> announces addition of 3 divalproex ... 2020 forecasts for global markets as well as ... along with analysis of major players. ...
(Date:10/9/2015)... 9, 2015  The Centers for Disease Control ... and Zoonotic Infectious Diseases, Office of Advanced Molecular ... a research collaboration to evaluate the performance of ... this research collaboration is to evaluate the utility ... health and infectious disease applications. This collaboration will ...
(Date:10/9/2015)... ClinicalKey Nursing debuts at ...   Elsevier , a world-leading provider of ... ClinicalKey for Nursing , a new clinical reference platform ... unique needs of nursing professionals. Attendees of the ANCC ... Oct. 7-9, will have the opportunity to demo ClinicalKey Nursing ...
Breaking Medicine Technology:
... plan for various study outcomes, MEXICO CITY, Aug. ... a new report, Anticipating the Results of PrEP,Trials, calling ... and advocates to prepare for initial,results - expected as ... drugs being tested for HIV prevention, known as PrEP ...
... is pleased,to announce the dosing of the first patient ... of AEG35156, a second generation antisense,therapeutic targeting XIAP, a ... The study, made possible, in part, by funding from ... Multicenter, Open-Label Study,of the X- Linked Inhibitor of Apoptosis ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... ... welcoming individuals from all walks of life to save money on the high ... of $25 per month per medication, individuals and families can receive their medications ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental health hospital ... mental illness, the stigma associated with mental illness causes many to hide away in ... importance of supporting teens with mental illness , providing teens with comprehensive diagnostic ...
(Date:10/9/2015)... Colorado (PRWEB) , ... October 09, 2015 , ... ... Station, one of the oldest and largest recreational dispensaries in Colorado, says the ... cannabis business is growing rapidly and maturing into a legitimate industry. , ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... assisted living placement counseling, recently opened its newest office in Maryland – its ... care industry with a background as a project management technology consultant to many ...
(Date:10/9/2015)... ... ... Smanos was featured on NewsWatch as part of its monthly Tech Report, which features ... and special reporter for NewsWatch, conducted the review and shared with viewers how this ... age it’s more important than ever to keep homes and dorms safe and protected. ...
Breaking Medicine News(10 mins):
... of infamous psychological obedience study in 1960s , , MONDAY, ... as willing to follow orders to hurt others as they ... , In a replication of one of the most famous ... give what they believed were increasingly painful electric shocks to ...
... , WHAT: YEAR-IN-PREVIEW WEBINAR ... Wednesday, January 7, 2009 11:00 AM (U.S. Eastern Time) ... ENROLL: Please use the link below to register ... Millennium Research Group (MRG) complimentary webinar identifying the top 10 ...
... will be the subject of a policy forum sponsored ... January 13, 2009, from 3:00 p.m. until 4:30 p.m. ... Suites Resort, 5001 N. Scottsdale Road, Scottsdale, Arizona. This ... explore the relationship between health insurance coverage and access ...
... Mo., Jan. 5 The recent tragic death of Jett ... which he was diagnosed in early childhood. Kawasaki disease is ... the age of five. The disease occurs more often in ... and Korean descent. Although most children diagnosed with Kawasaki recover ...
... AUGUSTA, Ga. Just days after the first retinal ... start committing suicide and researchers believe their death may ... infection. , Understanding the cell death may also provide ... retina responds to assault, whether by infection or a ...
... WASHINGTON, Jan. 5 Despite a deepening recession, only ... raise less money this year than in 2008 said ... services for the poor and underinsured, according to a ... Philanthropy ( ).The overwhelming majority of AHP members ...
Cached Medicine News:
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
Medicine Products: